Advaxis, Inc. (NASDAQ:ADXS) dropped 5.4% during mid-day trading on Tuesday . The company traded as low as $1.91 and last traded at $1.94. Approximately 574,585 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 1,196,589 shares. The stock had previously closed at $2.05.
ADXS has been the topic of a number of analyst reports. Cantor Fitzgerald reduced their price target on Advaxis from $19.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 13th. ValuEngine raised Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, HC Wainwright set a $6.00 target price on Advaxis and gave the stock a “buy” rating in a research report on Wednesday, March 14th.
The company has a market cap of $101.49, a PE ratio of -0.83 and a beta of 1.06.
Advaxis (NASDAQ:ADXS) last issued its earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.06. Advaxis had a negative return on equity of 149.14% and a negative net margin of 940.64%. The business had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million. equities analysts forecast that Advaxis, Inc. will post -1.73 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Deutsche Bank AG raised its position in shares of Advaxis by 1,200.1% during the 4th quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock worth $1,326,000 after acquiring an additional 431,379 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Advaxis during the 4th quarter worth about $1,398,000. Capital Analysts LLC raised its position in shares of Advaxis by 2,214.3% during the 4th quarter. Capital Analysts LLC now owns 69,428 shares of the biotechnology company’s stock worth $3,962,000 after acquiring an additional 66,428 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Advaxis by 39.9% during the 4th quarter. Wells Fargo & Company MN now owns 66,206 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 18,892 shares in the last quarter. Finally, Cutler Capital Management LLC raised its position in shares of Advaxis by 51.8% during the 4th quarter. Cutler Capital Management LLC now owns 75,876 shares of the biotechnology company’s stock worth $215,000 after acquiring an additional 25,876 shares in the last quarter. 29.13% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Advaxis (ADXS) Trading Down 5.4%” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/03/22/advaxis-adxs-trading-down-5-4.html.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.